Lab Education
|
November 13, 2024

7 Lab Tests For Patients With a Family History of High Blood Pressure

Medically Reviewed by
Updated On
December 11, 2024

Hypertension is a global health concern, affecting approximately 1.28 billion adults worldwide. In the United States, nearly half of adults aged 18 and older have hypertension, with awareness, treatment, and control rates being suboptimal (40).

Individuals with a family history of hypertension are at a significantly increased risk of developing the condition themselves, owing to both genetic predispositions and shared environmental factors. Comprehensive laboratory testing screens patients with a familial predisposition to hypertension, helping to identify underlying conditions, assess overall cardiovascular risk, and guide personalized treatment strategies.Β 

Sign Up to Order Labs

[signup]

What Is Hypertension?

Blood pressure is the force exerted by circulating blood against the walls of the arteries as the heart pumps it throughout the body. It is measured using two numbers:Β 

  • Systolic Pressure: represents the pressure when the heart contracts and pumps blood
  • Diastolic Pressure: indicates the pressure when the heart is at rest between beatsΒ 

For example, a blood pressure reading of 120/80 mmHg denotes a systolic pressure of 120 mmHg and a diastolic pressure of 80 mmHg.

Hypertension is defined as sustained elevated blood pressure. According to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, hypertension is diagnosed when systolic blood pressure (SBP) is >130 mmHg or diastolic blood pressure (DBP) is >80 mmHg.Β 

Hypertension is categorized into different stages:

  • Normal: <120/80 mmHg
  • Elevated: SBP 120-129 mmHg and DBP <80 mmHg
  • Stage 1 Hypertension: SBP 130-139 mmHg or DBP 80-89 mmHg
  • Stage 2 Hypertension: SBP β‰₯140 mmHg or DBP β‰₯90 mmHg

Uncontrolled hypertension significantly increases the risk of:

  • Cardiovascular disease (CVD), including peripheral artery disease and heart attack (myocardial infarction)
  • Stroke
  • Kidney dysfunction, chronic kidney disease (CKD), and kidney failure
  • Other complications, such as vision loss and sexual dysfunction

Relevance of Family History in High Blood Pressure

A family history of hypertension significantly impacts the risk and progression of hypertension in individuals. Studies find that genes influence about 35-50% of a person's risk for developing high blood pressure.

The Tampere Adult Population Cardiovascular Risk Study demonstrated that individuals with a positive family history of hypertension had higher systolic and diastolic blood pressures and a greater annual increase in systolic blood pressure over a 15-year follow-up period compared to those without a family history. By age 50, the odds of diagnosed hypertension were significantly higher in those with a positive family history.Β 

The Framingham Heart Study further supports these findings, showing that early-onset hypertension in parents and grandparents increases the risk of hypertension in subsequent generations, even after adjusting for lifestyle factors. This transgenerational risk underscores the importance of considering family history in clinical evaluations.

Additionally, the ACC/AHA guidelines highlight family history as a fixed risk factor for hypertension, necessitating close monitoring and potentially earlier intervention in affected individuals.

Key Lab Tests for Patients With a Family History of Hypertension

These are seven essential laboratory tests necessary for screening, assessing risk, and managing patients with a familial predisposition to hypertension and elevated CVD risk.Β 

Advanced Lipid Profile

A lipid panel measures the levels of various lipids in the blood, including:

Dyslipidemia is a significant risk factor for atherosclerosis and subsequent CVD. Elevated LDL-C, triglycerides, and low HDL-C contribute to plaque formation and arterial stiffness, exacerbating hypertension and increasing CVD risk. (75)

Abnormal lipid levels guide the initiation and intensity of lipid-lowering therapies, primarily statins. For instance, an LDL-C >190 mg/dL typically warrants high-intensity statin therapy regardless of other risk factors. Elevated triglycerides may necessitate dietary modifications and consideration of fibrate therapy.

Optimal Values

  • Total Cholesterol: <200 mg/dL
  • LDL-C: <100 mg/dL
  • HDL-C: β‰₯60 mg/dL
  • Triglycerides: <150 mg/dL (1, 2)Β 

Advanced lipid testing includes measurements beyond the standard lipid profile, such as:

Advanced lipid parameters offer more precise risk stratification for atherosclerotic CVD. Smaller, denser LDL particles are more atherogenic, and elevated ApoB levels correlate with the number of atherogenic lipoprotein particles, providing a better prediction of CVD risk than LDL-C alone. (10, 31)Β 

Patients with elevated ApoB or numerous small, dense LDL particles may benefit from more aggressive lipid-lowering strategies, even if their LDL-C levels are not markedly elevated (3, 54). This could include higher doses of statins or the addition of other emerging lipid-lowering agents, such as ezetimibe or PCSK9 inhibitors, to achieve optimal lipid profiles.

Optimal Values

  • LDL Particle Size and Number: fewer, larger particles are preferable
  • ApoB: <90 mg/dL (7)Β 
  • ApoA1: 167-175 mg/dL (37)Β 

Comprehensive Metabolic Panel (CMP)

The CMP encompasses a group of tests that evaluate metabolic and organ function, including:

  • Blood Sugar: glucose
  • Electrolytes: sodium, potassium, chloride, calcium, bicarbonate (35)Β 
  • Renal Function: blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR) (21)Β 
  • Liver Function: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) (22)Β 

The CMP provides a broad assessment of metabolic health and helps identify secondary causes of hypertension. The ACC/AHA recommends laboratory measurements, including a CMP, for all patients with a new diagnosis of hypertension to facilitate CVD risk factor profiling, establish a baseline for medication use, and screen for secondary causes of hypertension.Β 

Results from a CMP can influence treatment decisions in several ways. Examples include:

  • Abnormal renal function tests (e.g., elevated creatinine) may prompt the use of renal-protective antihypertensives such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).Β 
  • Electrolyte imbalances, particularly hyperkalemia (high potassium), can influence the choice of diuretics and necessitate dose adjustments.Β 
  • Liver dysfunction may require careful selection of medications metabolized hepatically to avoid toxicity.

Hemoglobin A1c (HbA1c)

HbA1c measures glycated hemoglobin, reflecting average blood glucose levels over the past 2-3 months. It is primarily used for diagnosing and monitoring prediabetes and diabetes but also serves as a marker for cardiovascular risk.

Elevated HbA1c is associated with increased hypertension risk, even in non-diabetic individuals (41). Additionally, elevated HbA1c is correlated to dyslipidemia and elevated homocysteine, which collectively raise the risk of CVD, including coronary artery disease (CAD), ischemic heart disease, and ischemic stroke (58). The American Diabetes Association (ADA) notes that an HbA1c range of 5.7-6.4% identifies individuals at high risk for diabetes and cardiovascular outcomes.

Elevated HbA1c levels may prompt more aggressive lifestyle and pharmaceutical interventions, such as dietary changes, increased physical activity, natural supplements, and prescription medications, to reduce blood glucose, blood pressure, and overall CVD risk.Β 

Interpreting Values

  • Normal: <5.7%
  • Prediabetes: 5.7-6.4%
  • Diabetes: β‰₯6.5% (19)Β 

C-Reactive Protein (CRP)

CRP is an acute-phase reactant produced by the liver in response to inflammation. High-sensitivity CRP (hs-CRP) is a more precise measure used to assess low levels of inflammation, which is relevant for CVD risk assessment. (18)Β 

hs-CRP is an independent predictor of future cardiovascular events, including myocardial infarction and stroke. Elevated hs-CRP levels are associated with increased vascular inflammation, atherosclerosis, and subsequent cardiovascular events. (38, 39)Β 

CVD Risk Stratification Based on hs-CRP Levels

  • Low Risk: <1 mg/L
  • Average Risk: 1-3 mg/L
  • High Risk: >3 mg/L (18)

Several studies, including the JUPITER trial, have shown that reducing hs-CRP levels can significantly impact cardiovascular outcomes. The JUPITER trial demonstrated that statin therapy (rosuvastatin 20 mg/day) in individuals with elevated hs-CRP (>2 mg/L) but normal LDL-C levels resulted in a 44% reduction in the rate of first major cardiovascular events.Β 

This suggests that targeting inflammation through hs-CRP reduction can be beneficial in managing cardiovascular risk. Therefore, in the context of managing patients at risk of hypertension due to family history, elevated hs-CRP levels may prompt the initiation of statin therapy even if LDL-C levels are not elevated.

Thyroid Panel

Both hyperthyroidism and hypothyroidism can lead to elevated blood pressure. Hyperthyroidism increases cardiac output and systolic blood pressure, while hypothyroidism is associated with diastolic hypertension and increased arterial stiffness. (8)

Research has demonstrated a correlation between thyroid disease and hypertension rates. For instance, a study found that thyroid-stimulating hormone (TSH) levels on the high end of normal are associated with increased blood pressure and hypertension risk.Β 

Another study indicated that changes in free T3 (fT3) and free T4 (fT4) levels are independently related to the risk of incident hypertension in a euthyroid population.Β 

Additionally, reduced sensitivity to thyroid hormones has been linked to higher hypertension risk.

A family history of thyroid disease increases the risk of developing thyroid disorders, including autoimmune thyroid diseases like Hashimoto's thyroiditis and Graves' disease. One study found that first-degree relatives of patients with autoimmune thyroid diseases have a significantly higher risk of developing these conditions, with a 16-fold increased risk for children and a 15-fold increased risk for siblings.Β 

Optimal Values

  • TSH: 0.5-2.5 mIU/L
  • fT4: 1.0-1.7 mIU/L
  • fT3: 3.0-4.0 mIU/LΒ 
  • Anti-TPO: <35 IU/mL (34)Β 

Urinalysis

Urinalysis is a diagnostic test that involves the physical, chemical, and microscopic examination of urine. It provides valuable information about kidney function and can detect various conditions, including infections, kidney disease, and metabolic disorders.

Urinalysis can help identify early signs of kidney damage, such as proteinuria (high protein levels in the urine). Proteinuria, specifically microalbuminuria, can indicate glomerular damage and endothelial dysfunction, which are early features of essential hypertension.

Studies have shown strong correlations between proteinuria/microalbuminuria and hypertension outcomes. For instance, one study concluded that urinary albumin excretion predicts blood pressure progression and incident hypertension in nonhypertensive individuals. Another study found that urinary albumin, even when it is within the normal range, is an independent predictor of future hypertension.

Optimal Values

  • Urinary Albumin-to-Creatinine Ratio (UACR): <10 mg/g (63)Β 

Genetic Testing

Polygenic risk scores (PRS) aggregate the effects of numerous single nucleotide polymorphisms (SNPs) to quantify an individual's genetic predisposition to hypertension and CVD. These scores have been shown to improve risk prediction beyond traditional clinical risk factors. The AHA highlights that PRS can identify individuals at high risk for conditions like CAD, high cholesterol, and type 2 diabetes, even when traditional risk factors are not present. (52)Β 

Genome-wide association studies (GWAS) have identified over one thousand SNPs associated with blood pressure control. For example, the MTHFR C677T polymorphism is associated with an increased risk of hypertension and CVD. Individuals with the TT genotype have been shown to have higher blood pressure and increased central hemodynamic parameters compared to those with the CC or CT genotypes.

[signup]

Key Takeaways

  • Laboratory testing is paramount in managing patients with a family history of hypertension, as it enables early detection, accurate risk stratification, and informed treatment decisions that can mitigate the heightened risk of CVD.Β 
  • By adopting comprehensive lab screening protocols, clinicians can effectively identify and address underlying risk factors, ensuring that high-risk populations receive personalized and proactive care.Β 
  • Remember that family history is just one of many risk factors for high blood pressure. Regardless of genetic susceptibility, adopting a heart-healthy lifestyle through balanced nutrition, regular physical activity, and stress management can significantly lower the risk of developing high blood pressure, underscoring the importance of a holistic strategy in cardiovascular risk reduction (57).Β 
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!
  1. Achuff, J. (2024, February 5). How to test and interpret total cholesterol levels: A functional medicine perspective. Rupa Health. https://www.rupahealth.com/post/how-to-test-and-interpret-total-cholesterol-levels-a-functional-medicine-perspective
  2. Achuff, J. (2024, February 6). How to lower your patient's triglycerides using root cause medicine. Rupa Health. https://www.rupahealth.com/post/how-to-lower-your-patients-triglycerides-using-root-cause-medicine
  3. Ahmad, M., Sniderman, A. D., & Hegele, R. A. (2023). Apolipoprotein B in cardiovascular risk assessment. CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, 195(33), E1124. https://doi.org/10.1503/cmaj.230048
  4. American Diabetes Association Professional Practice Committee. (2023). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetesβ€”2024. Diabetes Care, 47(Supplement_1), S20–S42. https://doi.org/10.2337/dc24-s002
  5. Anderson, S. (2022, May 19). 6 Preventable Risk Factors Associated With Heart Attacks. Rupa Health. https://www.rupahealth.com/post/5-things-to-do-after-a-heart-attack
  6. Åsvold, B. O., BjΓΈro, T., Nilsen, T. I. L., et al. (2007). Association between Blood Pressure and Serum Thyroid-Stimulating Hormone Concentration within the Reference Range: A Population-Based Study. The Journal of Clinical Endocrinology & Metabolism, 92(3), 841–845. https://doi.org/10.1210/jc.2006-2208
  7. Bays, H. E., Jones, P. H., Brown, W. V., et al. (2014). National Lipid Association Annual Summary of Clinical Lipidology 2015. Journal of Clinical Lipidology, 8(6), S1–S36. https://doi.org/10.1016/j.jacl.2014.10.002
  8. Berta, E., Lengyel, I., Halmi, S., et al. (2019). Hypertension in Thyroid Disorders. Frontiers in Endocrinology, 10(482). https://doi.org/10.3389/fendo.2019.00482
  9. Blake, K. (2023, April 28). What Is a Heart Healthy Diet and Who Should Follow One? Rupa Health. https://www.rupahealth.com/post/what-is-a-heart-healthy-diet-and-who-should-follow-one
  10. Chandra, A., & Rohatgi, A. (2014). The Role of Advanced Lipid Testing in the Prediction of Cardiovascular Disease. Current Atherosclerosis Reports, 16(3), 394. https://doi.org/10.1007/s11883-013-0394-9
  11. Cloyd, J. (2023, April 10). A Functional Medicine Hypertension Protocol. Rupa Health. https://www.rupahealth.com/post/functional-medicine-hypertension-protocol
  12. Cloyd, J. (2023, May 18). Top Evidence-Based Herb and Supplements For Heart Health. Rupa Health. https://www.rupahealth.com/post/evidence-based-herbal-supplements-and-their-potential-benefits-for-heart-health
  13. Cloyd, J. (2023, June 19). A Functional Medicine Post Stroke Protocol: Testing, Therapeutic Diet, and Integrative Therapy Options. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-post-stroke-protocol-testing-supplements-and-integrative-therapy-options
  14. Cloyd, J. (2023, July 3). The Role of Physical Activity in Promoting Heart Health. Rupa Health. https://www.rupahealth.com/post/the-role-of-physical-activity-and-exercise-in-promoting-heart-health-including-the-use-of-alternative-exercise-modalities-such-as-tai-chi-and-qigong
  15. Cloyd, J. (2023, August 21). Thyroid Hormone Testing Guide: A Comprehensive Review of How to Test for Thyroid Hormones. Rupa Health. https://www.rupahealth.com/post/thyroid-hormone-testing-guide-a-comprehensive-review-of-how-to-test-for-thyroid-hormones
  16. Cloyd, J. (2023, October 23). What Do Homocysteine Test Results Tell Us? Rupa Health. https://www.rupahealth.com/post/what-do-homocysteine-test-results-tell-us
  17. Cloyd, J. (2023, December 5). Inflammation and Heart Disease: A Functional Medicine Approach to Prevention and Treatment. Rupa Health. https://www.rupahealth.com/post/inflammation-and-heart-disease-a-functional-medicine-approach-to-prevention-and-treatment
  18. Cloyd, J. (2023, December 11). How to Interpret Your CRP Blood Test. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-crp-blood-test
  19. Cloyd, J. (2023, December 26). How to Interpret An HbA1c Test and What it Means For Your Patient's Health. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-an-hba1c-test-and-what-it-means-for-your-patients-health
  20. Cloyd, J. (2024, January 2). A functional medicine approach to prediabetes. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-prediabetes
  21. Cloyd, J. (2024, January 19). Understanding the Role of Kidney Function Tests in Comprehensive Health Assessments. Rupa Health. https://www.rupahealth.com/post/understanding-the-role-of-kidney-function-tests-in-comprehensive-health-assessments
  22. Cloyd, J. (2024, January 22). Interpreting Liver Enzyme Tests: ALT, AST, and ALP in Liver Health Monitoring. Rupa Health. https://www.rupahealth.com/post/interpreting-liver-enzyme-tests-alt-ast-and-alp-in-liver-health-monitoring
  23. Cloyd, J. (2024, January 24). The Value of Urinalysis in Functional Medicine: A Tool for Comprehensive Health Assessment. Rupa Health. https://www.rupahealth.com/post/the-value-of-urinalysis-in-functional-medicine-a-tool-for-comprehensive-health-assessment
  24. Cloyd, J. (2024, February 28). The Link Between Erectile Dysfunction and Cardiovascular Disease: Understanding the Connection. Rupa Health. https://www.rupahealth.com/post/the-link-between-erectile-dysfunction-and-cardiovascular-disease-understanding-the-connection
  25. Cloyd, J. (2024, March 4). The Role of Statins in Managing High Cholesterol: Benefits and Side Effects. Rupa Health. https://www.rupahealth.com/post/the-role-of-statins-in-managing-high-cholesterol-benefits-and-side-effects
  26. Cloyd, J. (2024, March 5). How to lower LDL cholesterol naturally: Evidence-Based recommendations. Rupa Health. https://www.rupahealth.com/post/how-to-lower-ldl-cholesterol-naturally-evidence-based-recommendations
  27. Cloyd, J. (2024, March 6). How to Increase HDL Cholesterol: A Root Cause Medicine Approach. Rupa Health. https://www.rupahealth.com/post/how-to-increase-hdl-cholesterol-a-root-cause-medicine-approach
  28. Cloyd, J. (2024, August 29). High Blood Pressure: Comprehensive Guide for Practitioners and Patients. Rupa Health. https://www.rupahealth.com/post/high-blood-pressure-comprehensive-guide-for-practitioners-and-patients
  29. Cloyd, J. (2024, September 10). High Protein in Urine Explained: What It Means and How to Manage It. Rupa Health. https://www.rupahealth.com/post/high-protein-in-urine-explained-what-it-means-and-how-to-manage-it
  30. Cloyd, J. (2024, September 12). https://www.rupahealth.com/post/high-intensity-statins-a-guide-for-optimal-heart-health. Rupa Health. https://www.rupahealth.com/post/high-intensity-statins-a-guide-for-optimal-heart-health
  31. Cloyd, K. (2023, December 19). How to interpret your lipid panel results. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-lipid-panel-results
  32. Creedon, K. (2022, July 14). Simple lifestyle changes that can help keep high blood pressure under control. Rupa Health. https://www.rupahealth.com/post/simple-lifestyle-changes-that-can-help-control-high-blood-pressure
  33. Daglis, S. (2024, March 12). Emerging Therapies for Lipid Disorders: PCSK9 Inhibitors and Beyond. Rupa Health. https://www.rupahealth.com/post/emerging-therapies-for-lipid-disorders-pcsk9-inhibitors-and-beyond
  34. DeCesaris, L. (2022, August 8). Worried About Your Thyroid Health? Ask Your Doctor For These 3 Thyroid Labs. Rupa Health. https://www.rupahealth.com/post/treating-the-thyroid-naturally
  35. DePorto, T. (2023, January 5). Electrolytes Imbalance: Symptoms & How to Treat It. Rupa Health. https://www.rupahealth.com/post/electrolytes
  36. Dittmar, M., Libich, C., Brenzel, T., et al. (2011). Increased Familial Clustering of Autoimmune Thyroid Diseases. Hormone and Metabolic Research, 43(03), 200–204. https://doi.org/10.1055/s-0031-1271619
  37. Faaborg-Andersen, C. C., Liu, C., Subramaniyam, V., et al. (2022). U-shaped relationship between apolipoprotein A1 levels and mortality risk in men and women. European Journal of Preventive Cardiology, 30(4), 293–304. https://doi.org/10.1093/eurjpc/zwac263
  38. Genest, J. (2010). C-reactive protein: Risk factor, biomarker and/or therapeutic target? Canadian Journal of Cardiology, 26, 41A44A. https://doi.org/10.1016/s0828-282x(10)71061-8
  39. Hage, F. G. (2013). C-reactive protein and Hypertension. Journal of Human Hypertension, 28(7), 410–415. https://doi.org/10.1038/jhh.2013.111
  40. High Blood Pressure Facts. (2024, May 15). Centers for Disease Control and Prevention. https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html
  41. Huang, X., Qin, C., Guo, X., et al. (2023). Association of hemoglobin A1c with the incidence of hypertension: A large prospective study. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.1098012
  42. Hypertension. (2023, March 16). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hypertension
  43. Karanchi, H., Muppidi, V., & Wyne, K. (2023, August 14). Hypertriglyceridemia. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459368/
  44. Khakham, C. (2023, March 28). An integrative medicine approach to kidney disease. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-kidney-disease
  45. Khakham, C. (2023, April 6). Understanding Your Risk of Cardiovascular Disease With Functional Medicine Labs. Rupa Health. https://www.rupahealth.com/post/understanding-your-risk-of-cardiovascular-disease-with-functional-medicine-labs
  46. Khakham, C. (2023, May 11). Exploring Integrative Medicine Strategies for Optimal Heart Health: The Role of Specialty Lab Testing and Stress Reduction Techniques. Rupa Health. https://www.rupahealth.com/post/exploring-integrative-medicine-strategies-for-optimal-heart-health-the-role-of-specialty-lab-testing-and-stress-reduction-techniques
  47. Know Your Risk Factors for High Blood Pressure. (2024, May 20). American Heart Association. https://www.heart.org/en/health-topics/high-blood-pressure/know-your-risk-factors-for-high-blood-pressure
  48. Kunnas, T., & Nikkari, S. T. (2023). Family history of hypertension enhances age-dependent rise in blood pressure, a 15-year follow-up, the Tampere adult population cardiovascular risk study. Medicine (Baltimore), 102(39), e35366–e35366. https://doi.org/10.1097/md.0000000000035366
  49. Magerman, R. (2024, June 27). How to Use Advanced Lipid Testing to Assess Your Cardiac Risk. Rupa Health. https://www.rupahealth.com/post/advanced-lipid-testing-cardiac-risk
  50. Matthews, R. (2022, October 10). MTHFR Gene Variants: Diagnosis & Treatment. Rupa Health. https://www.rupahealth.com/post/mthfr-gene-variants-diagnosis-treatment
  51. Niiranen, T. J., McCabe, E. L., Larson, M. G., et al. (2017). Risk for hypertension crosses generations in the community: a multi-generational cohort study. European Heart Journal, 38(29), 2300–2308. https://doi.org/10.1093/eurheartj/ehx134
  52. O'Sullivan, J. W., Raghavan, S., Marquez-Luna, C., et al. (2022). Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 146(8). https://doi.org/10.1161/cir.0000000000001077
  53. Oparil, S., Acelajado, M. C., Bakris, G. L., et al. (2019). Hypertension. Nature Reviews Disease Primers, 4(4), 1–48. https://doi.org/10.1038/nrdp.2018.14
  54. Otvos, J. D., Mora, S., Shalaurova, I., et al. (2011). Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. Journal of Clinical Lipidology, 5(2), 105–113. https://doi.org/10.1016/j.jacl.2011.02.001
  55. Padmanabhan, S., & Dominiczak, A. F. (2020). Genomics of hypertension: the road to precision medicine. Nature Reviews Cardiology, 18. https://doi.org/10.1038/s41569-020-00466-4
  56. Pappan, N., Awosika, A. O., & Rehman, A. (2023). Dyslipidemia. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK560891/
  57. Pazoki, R., Dehghan, A., Evangelou, E., et al. (2018). Genetic Predisposition to High Blood Pressure and Lifestyle Factors. Circulation, 137(7), 653–661. https://doi.org/10.1161/circulationaha.117.030898
  58. Prasad, K. (2018). Does HbA1cc Play a Role in the Development of Cardiovascular Diseases? Current Pharmaceutical Design, 24(24), 2876–2882. https://doi.org/10.2174/1381612824666180903121957
  59. Ranasinghe, P., Cooray, D. N., Jayawardena, R., et al. (2015). The influence of family history of Hypertension on disease prevalence and associated metabolic risk factors among Sri Lankan adults. BMC Public Health, 15(1). https://doi.org/10.1186/s12889-015-1927-7
  60. Ridker, P. M., Danielson, E., Fonseca, F. A. H., et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, 359(21), 2195–2207. https://doi.org/10.1056/NEJMoa0807646
  61. Romero-Cabrera, J. L., Ankeny, J., FernΓ‘ndez-Montero, A., et al. (2022). A Systematic Review and Meta-Analysis of Advanced Biomarkers for Predicting Incident Cardiovascular Disease among Asymptomatic Middle-Aged Adults. International Journal of Molecular Sciences, 23(21), 13540. https://doi.org/10.3390/ijms232113540
  62. Rooney, M., Hughes, C. F., Strain, J. J., et al. (2022). Impact of the MTHFR C677T polymorphism on blood pressure and related central haemodynamic parameters in healthy adults. Journal of Human Nutrition and Dietetics, 35(4), 689–700. https://doi.org/10.1111/jhn.13061
  63. Sehtman‐Shachar, D. R., Yanuv, I., Schechter, M., et al. (2024). Normoalbuminuriaβ€”is it normal? The association of urinary albumin within the "normoalbuminuric" range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis. Diabetes Obesity and Metabolism, 26(10), 4225–4240. https://doi.org/10.1111/dom.15752
  64. Takase, H., Sugiura, T., Ohte, N., et al. (2015). Urinary Albumin as a Marker of Future Blood Pressure and Hypertension in the General Population. Medicine, 94(6), e511. https://doi.org/10.1097/MD.0000000000000511
  65. Tingle, R. (2022, June 6). 10 Type 2 Diabetes Risk Factors You May Not Know About. Rupa Health. https://www.rupahealth.com/post/what-causes-type-2-diabetes
  66. Wang, T. J., Evans, J. C., Meigs, J. B., et al. (2005). Low-Grade Albuminuria and the Risks of Hypertension and Blood Pressure Progression. Circulation, 111(11), 1370–1376. https://doi.org/10.1161/01.cir.0000158434.69180.2d
  67. Wang, Y., Gu, Y., Zhang, Q., et al. (2021). The association between longitudinal trends of thyroid hormones levels and incident hypertension in a euthyroid population. Journal of Human Hypertension, 35(12), 1159–1169. https://doi.org/10.1038/s41371-020-00474-4
  68. Weinberg, J. L. (2022, March 18). Fatigue, weight gain, depression, and brain fog are common signs of This autoimmune disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-hashimotos-disease
  69. Weinberg, J. L. (2022, September 7). An Integrative Medicine Approach to Hypothyroidism. Rupa Health. https://www.rupahealth.com/post/understanding-hypothyroidism-and-how-to-treat-it-naturally
  70. Weinberg, J. L. (2023, January 24). Functional Medicine Treatment for Graves' Disease. Rupa Health. https://www.rupahealth.com/post/functional-medicine-treatment-for-graves-disease
  71. Weinberg, J. L. (2023, February 7). A Functional Medicine Protocol for Hyperthyroidism. Rupa Health. https://www.rupahealth.com/post/5-functional-medicine-labs-that-can-assist-a-root-cause-treatment-for-hyperthyroidism
  72. Weinberg, J. L. (2024, August 2). Managing High Potassium: A Guide for Patients and Practitioners. Rupa Health. https://www.rupahealth.com/post/managing-high-potassium-a-guide-for-patients-and-practitioners
  73. Wenzel, R. R. (2005). Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy. Drugs, 65(Suppl 2), 29–39. https://doi.org/10.2165/00003495-200565002-00005
  74. Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71(6). https://doi.org/10.1161/hyp.0000000000000065
  75. WyszyΕ„ska, J., Łuszczki, E., Sobek, G., et al. (2023). Association and Risk Factors for Hypertension and Dyslipidemia in Young Adults from Poland. International Journal of Environmental Research and Public Health, 20(2), 982. https://doi.org/10.3390/ijerph20020982
  76. Yoshimura, H. (2023, March 30). The Importance of Running Comprehensive Metabolic Panel (CMP) on Your Patients. Rupa Health. https://www.rupahealth.com/post/the-importance-of-running-comprehensive-metabolic-panel-cmp-on-your-patients
  77. Yoshimura, H. (2024, March 12). What is Secondary Hypertension?: Testing and Treatments. Rupa Health. https://www.rupahealth.com/post/what-is-secondary-hypertension-testing-and-treatments
  78. Yu, L., Pan, G., Li, Z., et al. (2023). Impaired Sensitivity to Thyroid Hormones Is Associated With Different Grades of Hypertension: a multicenter cross-sectional study. Nutrition Metabolism and Cardiovascular Diseases, 34(7). https://doi.org/10.1016/j.numecd.2023.12.019
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless β€” and best of all, it's free for practitioners.

Latest Articles

View more on Lab Education
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey practitioners! πŸ‘‹ Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.

Hey practitioners! πŸ‘‹ Join Dr. Terry Wahls for a 3-week bootcamp on integrating functional medicine into conventional practice, focusing on complex cases like Multiple Sclerosis. Learn to analyze labs through a functional lens, perform nutrition-focused physical exams, and develop personalized care strategies. Register Here.